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Abstract 
Background: Many patients in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) had 
a significant improvement (> 10%) in the left ventricular ejection fraction (LVEF) during the course of 
the study, but the factors and outcomes associated with such improvement are uncertain.
Methods: We examined factors and rates of mortality, cause-specific mortality, and implantable 
cardioverter-defibrillator (ICD) shocks associated with improvement in LVEF by analyzing patients 
in the SCD-HeFT who were randomized to placebo or an ICD and who had an LVEF checked during 
follow-up. 
Results: During a median follow-up of 3.99 years, of 837 patients who had at least two follow-up LVEF 
measurements, 276 (33%) patients had > 10% improvement in LVEF and 561 (67%) patients had no 
significant change in LVEF. Factors significantly associated with LVEF improvement included female 
sex, white race, history of hypertension, a QRS duration < 120 ms, and beta-blocker use. Improvement 
in LVEF was associated with a significant improvement in survival. There was no significant associa-
tion between improvement in LVEF and cause-specific death, but there was a significant association 
between improvement in LVEF and reduced risk of receiving appropriate ICD shocks. 
Conclusions: About a third of patients in this analysis, who were randomized to placebo or an ICD 
in SCD-HeFT, had a significant improvement in LVEF during follow-up; improvement in LVEF was 
associated with improved survival but not with cause-specific death, and with decreased likelihood of 
receiving appropriate ICD shocks. (Cardiol J)
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Introduction
Treatment guidelines for the prevention of 
sudden cardiac death in patients with heart fail-
ure and reduced left ventricular ejection fraction 
(LVEF) have been informed by the results of vari-
ous groundbreaking clinical trials [1–3]. One such 
trial is the pivotal Sudden Cardiac Death in Heart 
Failure Trial (SCD-HeFT), which showed a 23% 
relative risk reduction in mortality with an implant-
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Patients in the amiodarone arm were excluded 
from this analysis due to the difficulty to adequately 
adjust for the confounding factor that amiodarone 
may have on our results. In addition, prior studies 
have shown increased risk of mortality with ami-
odarone, especially in patients with NYHA class III 
symptoms [2, 5].
While for the primary analysis we defined 
LVEF improvement as > 10%, we considered 
another definition based on a recent report from 
the Journal of the American College of Cardiology 
(JACC) Scientific Expert Panel on Heart Failure 
with Recovered Left Ejection Fraction, which 
provided a working definition of heart failure 
with recovered LVEF as: (1) documentation of 
a decreased LVEF < 40% at baseline, (2) ≥ 10% 
absolute improvement in LVEF, and (3) a second 
measurement of LVEF > 40% [6]. 
In this analysis, the main outcome was all-
-cause mortality. Other outcomes of interest in-
cluded cause-specific mortality and appropriate 
ICD shocks. Deaths were classified as cardiac or 
non-cardiac death, and when the event was cardiac, 
it was further classified as arrhythmic cardiac 
death, which includes death due to ventricular 
tachyarrhythmia or bradyarrhythmia, and non-
-arrhythmic cardiac death, which includes heart 
failure, non-arrhythmic non-heart failure, and other 
cardiac causes [7]. 
Per the SCD-HeFT protocol, the modality to 
measure LVEF at baseline and during follow-up was 
not specified. In the majority of patients, the base-
line LVEF was measured by an echocardiogram 
(n = 1461), while the remainder were measured 
by contrast angiography (n = 436) and radionuclide 
angiography (n = 616). While granular data on the 
modality used to measure follow-up LVEF were not 
available, the vast majority of LVEF assessments 
during follow-up were done by echocardiography.
For descriptive analyses, we fit a linear mixed-
-effects model for the log-transformed LVEF and 
used the estimated slopes to stratify patients into 
groups consisting of patients with an increase 
in LVEF by > 10% vs. not. We log-transformed 
LVEF measurements and plotted the transformed 
measurements for each patient against time, and 
a best-fit line was obtained. The slope of the line 
was used to assess the overall change in LVEF over 
time, even if the LVEF initially decreased and then 
increased, or vice versa, which was then used to 
determine whether the patients showed > 10% or 
≤ 10% improvement.
We compared these LVEF groups with descrip-
tive statistics, with means and standard deviations 
able cardioverter-defibrillator (ICD) in patients 
with New York Heart Association (NYHA) class II 
or III heart failure and LVEF ≤ 35% despite optimal 
medical therapy [2]. However, there is a subset of 
patients who receive an ICD for these criteria who 
later have improvement in LVEF to > 35%. The fac-
tors and outcomes associated with this improvement 
are not completely understood. A prior study showed 
that patients with heart failure with reduced ejection 
fraction, who later demonstrate recovery of LVEF 
above 40% have a lower rate of all-cause mortality 
and fewer hospitalizations than patients with heart 
failure with preserved ejection fraction (HFpEF) or 
heart failure with a persistently reduced ejection 
fraction (HFrEF) [4]. These findings suggest that an 
improved LVEF, even if it remains below normal, is 
associated with increased survival in patients with 
heart failure. However, this study was limited by 
the single-center retrospective study design. The 
SCD-HeFT overcomes these limitations by being 
a randomized clinical trial and by enrolling and fol-
lowing patients with a reduced LVEF from multiple 
medical centers. In this study, we aimed to examine 
factors and outcomes associated with a significant 
improvement in LVEF (> 10%) in SCD-HeFT. This 
magnitude in LVEF improvement was chosen at the 
inception of this analysis and was based on clinical 
judgment of what is considered meaningful LVEF 
improvement that is not due to errors in measuring 
LVEF while preserving a reasonable sample size.
Methods
Briefly, SCD-HeFT enrolled 2521 patients 
with NYHA class II or III heart failure due to 
ischemic or non-ischemic cardiomyopathy and 
an LVEF of ≤ 35%, who were randomly assigned 
to placebo (n = 847), amiodarone (n = 845), or 
a shock only, single-lead ICD (n = 829). All patients 
received optimal medical therapy at the time for 
heart failure. Patients were enrolled in SCD-HeFT 
from September 16, 1997, to July 18, 2001 and all 
patients were followed until October 31, 2003.
We selected patients from SCD-HeFT who 
were in the placebo or ICD arms and had at least 
three recorded measurements of LVEF during 
the course of the study with one measurement 
taken at baseline and at least two measurements 
obtained during follow-up. These follow-up LVEF 
measurements were performed ad hoc and were 
not mandated per the SCD-HeFT protocol. We 
required patients to have two follow-up LVEF 
measurements to decrease variability in these 
measurements and the likelihood of mis-readings.
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for continuous variables and counts and proportions 
for the categorical variables. In unadjusted analy-
ses, we obtained Kaplan-Meier survival curves 
comparing the two LVEF groups and examined the 
mode of death with cumulative incidence functions.
In adjusted analyses, to examine all-cause mor-
tality, we used joint longitudinal-survival models 
[8–10]. Such models have two components: a model 
for the longitudinal LVEF trajectory and a model for 
the survival data that incorporates features of the 
longitudinal LVEF model as predictors. With joint 
models, we note that the regression parameters for 
both the time-to-event and longitudinal outcomes 
are estimated jointly, unlike the procedure adopted 
for the descriptive analysis. Specifically, we mod-
eled the log-transformed LVEF as a linear mixed-
-effects model regressed on time since randomiza-
tion and baseline variables, and we used a Weibull 
proportional hazards survival regression model 
for time to death from all causes regressed on the 
subject-specific intercept and slope, dichotomized 
based on > 10% improvement in LVEF versus 
≤ 10% improvement, from the longitudinal LVEF 
model and baseline variables including treatment 
assignment, age, sex, race, history of hypertension, 
diabetes, pulmonary disease, smoking, ischemic 
heart disease, prior myocardial infarction (MI), 
prior coronary artery bypass grafting (CABG), prior 
percutaneous coronary intervention (PCI), NYHA 
class of heart failure, QRS duration, baseline LVEF, 
and treatment with beta-blockers, diuretics, or 
angiotensin-converting enzyme inhibitors (ACEI). 
To examine cause-specific mortality, we uti-
lized joint longitudinal competing risks survival 
models, which were fit under the Bayesian ap-
proach using relatively non-informative priors with 
JAGS and the R-package rjags.
To examine the risk of appropriate ICD ther-
apy, we fitted a mixed-effects model for the log-
transformed LVEF regressed on time since ran-
domization and adjusted for baseline covariates, 
and a logistic regression model for the outcome 
of appropriate shocks regressed on the subject-
specific intercept and slope, dichotomized based on 
> 10% improvement in LVEF vs. ≤ 10% improve-
ment. The variables included in this model were 
sex, age, race, presence or absence of ischemic 
heart disease, QRS duration, NYHA class of heart 
failure, history of smoking, diabetes, hypertension, 
pulmonary disease, prior MI, CABG, or PCI, and 
treatment with beta-blockers or ACEI. Patients 
who were classified as having received appropriate 
shock therapy were those who had documented 
evidence of appropriate shock therapy, in the pres-
ence or absence of other inappropriately delivered 
ICD therapy. Patients not in this group included 
those who received only inappropriately delivered 
shock therapy or no therapy at all.
All analyses were repeated in the subset of 
patients (n = 248) with at least one follow-up LVEF 
measurement of > 40%.
Results
Baseline characteristics of patients included 
(n = 837) and excluded (n = 839) from our analysis 
due to having fewer than three LVEF measure-
ments are shown in Supplementary Table 1. 
Compared with patients who were excluded from 
the analysis, those who were included were more 
likely to be white and to have left bundle branch 
block and a higher baseline LVEF (25% vs. 23%). 
The included patients had lower rates of hyperten-
sion, diabetes, pulmonary disease, and ischemic 
heart disease, as well as lower baseline blood urea 
nitrogen and creatinine.
During a median follow-up of 3.99 years, 837 
patients had at least one initial and two follow-up 
LVEF measurements. The average time to first 
follow-up LVEF was 1.02 ± 0.28 years, second fol-
low-up was 2.39 ± 0.57 years, and third follow-up 
was 3.04 ± 0.98 years. The median follow-up times 
for patients included in this study were similar 
between patients with or without > 10% improve-
ment in LVEF (4.04 vs. 3.97 years, respectively). 
Of these patients, 276 (33% of all patients, of whom 
149 had an ICD) had a 10% improvement in LVEF 
and 561 (67% of all patients, of whom 267 had an 
ICD) had no significant change in LVEF. Of the 
276 patients who demonstrated an improvement 
in LVEF > 10%, only 10 had a final LVEF that re-
mained below 35%. The baseline characteristics of 
the patients in the two groups are listed in Table 1.
In the adjusted longitudinal model, there was 
a significant association between improvement 
in LVEF and female sex (p = 0.003, 1.09, 95% 
confidence interval [CI] 1.03–1.14), white race 
(p < 0.001, 1.13, 95% CI 1.08–1.19), history of 
hypertension (p < 0.001, 1.10, 95% CI 1.05–1.14), 
a QRS duration < 120 ms (p < 0.001, 1.16, 95% CI 
1.12–1.20), and beta-blocker use (p = 0.01, 1.05, 
95% CI 1.01–1.10). Notably, the type of cardio-
myopathy (ischemic vs. non-ischemic) and prior 
coronary interventions were not associated with 
LVEF improvement.
In the adjusted survival model, improvement 
in LVEF was associated with a significant improve-
ment in survival (hazard ratio [HR] 0.58, 95% CI 
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0.35–0.96). Additionally, there was a significant 
negative association between baseline LVEF and 
all-cause mortality. Specifically, patients with a 10% 
higher baseline LVEF had a lower mortality risk 
(HR 0.87, 95% CI 0.84–0.91). Importantly, ICD use 
was significantly associated with improved survival 
independently of change in LVEF and other clinical 
variables (HR 0.62, 95% CI 0.43–0.91).
Kaplan-Meier survival curves for the two 
groups of interest are shown in Figure 1. At 5 years, 
the survival probability for patients with > 10% 
improvement in LVEF was 0.90 (95% CI 0.85–0.95) 
while the survival probability for patients with 
no change in LVEF was 0.77 (95% CI 0.72–0.81), 
demonstrating that > 10% improvement in LVEF 
is associated with improved survival outcomes.
In the adjusted survival model, there was 
a significant negative association between baseline 
LVEF and rates of non-cardiac death, non-arrhyth-
mic cardiac death, and arrhythmic cardiac death. 
Specifically, patients with a 10% higher baseline 
LVEF had lower rates of non-cardiac death (HR 
0.95, 95% CI 0.91–0.98), non-arrhythmic cardiac 
death (HR 0.91, 95% CI 0.88–0.94), and arrhythmic 
cardiac death (HR 0.95, 95% CI 0.92–0.99). Howev-
er, there was no association between improvement 
in LVEF and non-cardiac death (HR 0.92, 95% CI 
0.61–1.41), non-arrhythmic cardiac death (HR 0.73, 
Table 1. Baseline characteristics between patient groups.
No change in LVEF  
(n = 561)
Increase in LVEF > 10%  
(n = 276)
P
Mean/Count SD/Percentage Mean/Count SD/Percentage
ICD 267 47.59 149 53.99 0.10
Age 59 16 58 16 0.50
Male 451 80.39 186 67.39 < 0.001
White 460 82 223 80.8 0.74
History of hypertension 285 50.8 153 55.43 0.23
History of diabetes 161 28.7 81 29.35 0.91
History of pulmonary disease 91 16.22 51 18.48 0.47
History of smoking 428 76.29 193 69.93 0.06
eGFR (0, 60) [mL/min] 175 31.36 72 26.18 0.14
eGFR ≥ 60 mL/min 383 68.64 203 73.82 —
Ischemic disease 309 55.08 115 41.67 <0.001
Prior CABG 153 27.27 59 21.38 0.08
Prior MI 275 49.02 97 35.14 < 0.001
Time MI (days)* 1652 2977.5 1510 2670 0.47
Prior PCI 126 22.46 42 15.22 0.02
History of syncope 0 0 0 0 NA
LVEF [%] 24 6 25 7 0.04
New York Heart Association 2 403 71.84 204 73.91 0.58
New York Heart Association 3 158 28.16 72 26.09 —
Anti-arrhythmic medication 0 0 0 0 NA
Beta-blockers 382 68.09 186 67.39 0.90
ACEI* 544 96.97 268 97.1 1.00
Diuretics 475 84.67 233 84.42 1.00
QRS duration [ms] 118 52 104 32 < 0.001
Right bundle branch block 30 5.35 13 4.71 0.82
Left bundle branch block 151 26.92 52 18.84 0.01
*Time MI: time from the most recent myocardial infarction to enrollment in SCD-HeFT; ACEI — angiotensin-converting enzyme inhibitor; 
CABG — coronary artery bypass grafting; eGFR — estimated glomerular filtration rate; ICD — implantable cardioverter-defibrillator;  
LVEF — left ventricular ejection fraction; MI — myocardial infarction; PCI — percutaneous coronary intervention
Figure 2. Cumulative incidence functions of cause-spe-
cific mode of death for left ventricular ejection fraction 
(LVEF) groups. Group 1 (solid lines) refers to patients 
who experienced no change (£ 10% improvement) in 
LVEF while Group 2 (dashed lines) refers to patients 
who demonstrated an improvement of > 10% in LVEF.
Figure 1. Kaplan-Meier survival curves for groups de-
fined by left ventricular ejection fraction (LVEF). The 
number of patients at risk for each year in each LVEF 
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95% CI 0.49–1.10), and arrhythmic cardiac death 
(HR 0.84, 95% CI 0.55–1.27). Cumulative incidence 
functions for cause-specific death between LVEF 
groups are shown in Figure 2.
Of 416 patients with an ICD, 96 received ap-
propriate ICD therapy. There was a significant asso-
ciation between improvement in LVEF > 10% and 
decreased likelihood of receiving appropriate ICD 
shocks (odds ratio [OR] 0.27, 95% CI 0.08–0.77). 
However, there was no association between base-
line LVEF and likelihood of receiving appropriate 
ICD shocks (OR 0.76, 95% CI 0.33–1.51).
Repeating all analyses in the subset of patients 
with at least one follow-up LVEF measurement 
of > 40% (n = 248, 206 had > 10% improvement 
in LVEF and 42 had ≤ 10% improvement in LVEF) 
showed an association between baseline LVEF and 
survival. However, there was no significant association 
between improvement in LVEF and overall survival, 
cause-specific death, and appropriate ICD shocks.
Discussion
This study demonstrates that a third of patients 
included in this analysis had > 10% improvement 
in LVEF, and factors associated with this improve-
ment are female sex, white race, QRS < 120 ms, 
history of hypertension, and beta-blocker usage. 
Additionally, we demonstrated that > 10% im-
provement in LVEF was associated with lower risk 
of all-cause mortality and decreased likelihood of 
receiving appropriate ICD therapy.
There is a growing body of evidence dem-
onstrating that patients with heart failure with 
recovered or significantly improved LVEF have 
a distinct clinical phenotype and physiology that 
are not properly captured or addressed in clinical 
trials [11–16]. Improve the Use of Evidence-Based 
Heart Failure Therapies in the Outpatient Set-
ting (IMPROVE HF) found that patients who had 
a > 10% improvement in LVEF were more likely 
to be women, have a non-ischemic etiology of heart 
failure, have no prior MI, have a lower ejction frac-
tion at baseline, and not be taking digoxin [14]. 
While both studies determined that factors such 
as age, diabetes, and renal insufficiency were not 
associated with LVEF improvement, some baseline 
patient characteristics associated with improved 
LVEF found in IMPROVE HF are not concordant 
with those found in our study, demonstrating the 
need for more investigations of this patient popula-
tion. Prior studies have shown that patients with 
improved LVEF have improved survival and lower 
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risk of all-cause, cardiovascular, and heart failure-
-related hospitalizations, cardiac transplantation, 
or left ventricular assist device implantation when 
compared with patients with HFrEF [4, 14, 17]. 
Additionally, in a post hoc analysis of SCD-HeFT 
by Adabag et al. [18], patients with an improved 
LVEF to > 35% had a similar survival benefit 
from an ICD to those who did not demonstrate this 
improvement. It is noteworthy that using an LVEF 
of > 35% as a definition for LVEF improvement 
does not normalize the magnitude of change across 
patients, which Adabag et al. [18] acknowledged 
as a limitation. For example, a patient with LVEF 
improvement from 34% to 36% and a patient with 
improvement from 18% to 36% were analyzed as 
being the same by Adabag et al. [18]. We believe 
that our inclusion criterion of at least two follow-up 
LVEF measurements and our definition of a clini-
cally significant improvement in LVEF as > 10% 
increase the likelihood that the measured change 
in LVEF and associated findings are real and clini-
cally meaningful. Therefore, our analysis adds to 
prior studies by using a better definition of LVEF 
improvement, further identifying factors associated 
with LVEF improvement, and demonstrating that 
LVEF improvement is associated with a decreased 
likelihood of receiving appropriate ICD shocks.
Left ventricular ejection fraction improvement 
in patients with a primary prevention ICD presents 
a dilemma to clinicians and patients when deciding 
to replace the ICD generator at the end of battery 
life [15, 19–22]. Naksuk et al. [23] demonstrated 
that patients who had an LVEF improvement to 
> 35% and an increase in > 10% from baseline 
LVEF had a similar survival benefit before and after 
ICD replacement when compared with patients who 
had no improvement in LVEF. Our results support 
these findings by showing that ICD use was signifi-
cantly associated with improved survival independ-
ent of change in LVEF and other clinical variables.
Whether LVEF improvement is associated 
with appropriate ICD therapies was examined 
by Schliamser et al. [24], who determined that 
while improvement in LVEF was associated with 
improved survival, it was not with a significant 
decrease in appropriate ICD shocks. These authors 
determined that rates of appropriate ICD therapy 
are similar between those with and without im-
provement in LVEF while we present evidence 
for a decreased incidence of receiving appropriate 
ICD therapy with improvement in LVEF. Although 
patients with > 10% improvement in LVEF in our 
study experienced a lower incidence of appropriate 
ICD therapy, there was still a clear survival benefit 
to having an ICD; therefore, this finding does not 
justify forgoing ICD generator replacement at the 
end of battery life.
Limitations of the study 
There are several limitations to this analysis. 
This was a retrospective analysis of prospectively 
collected data; therefore, we cannot rule out re-
sidual confounding factors and selection bias. We 
were not able to examine subgroups of interest 
like patients who experience an improvement of 
> 10% yet remain beneath an LVEF of 35% (10 out 
of 276 patients).
Follow-up LVEF assessment was not protocol 
driven, potentially leading to other sources of bias. 
Also, the observed changes in LVEF, read at enroll-
ing centers and not at a central core facility, may 
partially be the result of differences in measure-
ment technique or user variability. Approximately 
50% of patients included in this analysis had is-
chemic heart disease, and data regarding the revas-
cularization procedures conducted during follow-up 
were unavailable. Additionally, specific data regard-
ing heart rhythm, therapeutic procedures, and 
other drugs including digoxin, angiotensin receptor 
blockers, and aldosterone antagonists were also 
unavailable. Some may critique our definition of 
an improvement in LVEF. We note that the > 10% 
improvement in LVEF was chosen at the inception 
of this analysis because it was thought to be less 
prone to errors in reading (e.g. from choosing a 5% 
change). In fact, our analysis provides evidence that 
a > 10% change in LVEF is associated with changes 
in clinical outcomes such as mortality and rates of 
appropriate ICD therapy. Patients included in this 
analysis had at least two follow-up LVEF measure-
ments, which may have introduced selection-bias 
against patients who died prior to having a repeat 
LVEF measurements, and it may reflect differences 
in overall quality of care. Although repeating the 
analyses in the subset of patients with at least one 
follow-up LVEF > 40% showed that there was no 
significant association between improvement in 
LVEF and overall survival, cause-specific death, 
and appropriate ICD shocks, these analyses were 
limited by the small sample size. Larger studies 
are needed to examine the association between 
LVEF improvement and outcomes in patients with 
at least one follow-up LVEF > 40%. Finally, optimal 
medical therapy of heart failure has significantly 
changed since the completion of SCD-HeFT, which 
may further influence factors that predict LVEF 
improvement and limit the applicability of these 
findings to heart failure patients today. 
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Conclusions
About a third of patients in this analysis, who 
were randomized to placebo or an ICD in SCD-HeFT, 
had > 10% improvement in LVEF during follow-up. 
Improvement in LVEF was associated with added 
survival benefit and decreased likelihood of receiv-
ing appropriate ICD shocks; however, there was no 
association with decreased risk of non-cardiac death 
and arrhythmic- and non-arrhythmic-related cardiac 
death. While female sex, white race, QRS < 120 ms, 
history of hypertension, and beta-blocker usage are 
associated with LVEF improvement, future studies 
should determine whether additional factors and 
tests can improve the prediction of LVEF improve-
ment and associated outcomes.
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